T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers is a paper indexed in ScholarIQ from OpenAlex.
How many citations does T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers have?
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers has 484 citations in the OpenAlex counts ScholarIQ stores.
When was T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers published?
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers has 2009 year in the ScholarIQ index.
What is the open-access status of T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers?
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers has gold oa status in the ScholarIQ index.
What is the DOI of T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers?
The DOI for T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers is on the source record.
What is the PMID of T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers?
The PMID for T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers is on the source record.
What is the OpenAlex record for T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers?
The OpenAlex for T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers is on the source record.